Cat. No.: HY-10297

Omipalisib

(Synonyms: GSK2126458; GSK458)

20 Cited Publications

Customer Review

Based on 20 publication(s) in Google Scholar

Omipalisib (GSK2126458) is an orally active and highly selective inhibitor of PI3K with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110α/β/δ/γ, mTORC1/2, respectively. Omipalisib has anti-cancer activity.

For research use only. We do not sell to patients.

Purity: 99.94%
CAS No.: 1086062-66-9
Formula: C₂₅H₁₇F₂N₅O₃S
Molecular Weight:505.50

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Omipalisib Chemical Structure

CAS No.: 1086062-66-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (20)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

p110α

0.019 nM (Ki)

p110α-E545K

0.008 nM (Ki)

p110α-E542K

0.008 nM (Ki)

p110α-H1047R

0.009 nM (Ki)

p110β

0.13 nM (Ki)

p110δ

0.024 nM (Ki)

p110γ

0.06 nM (Ki)

mTORC1

0.18 nM (Ki)

mTORC2

0.3 nM (Ki)

All PI3K Isoforms :

All mTOR Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	26.6 nM Compound: GSK; GSK-2126458	Growth inhibition of human A549 cells harboring wild type p110alpha and PTEN measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay Growth inhibition of human A549 cells harboring wild type p110alpha and PTEN measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay	[PMID: 33360802]
A549	IC₅₀	0.6 μM Compound: GSK2126458	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 26819001]
A549	IC₅₀	0.86 μM Compound: Omipalisib	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31097403]
A549	IC₅₀	140 nM Compound: GSK-2126458	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 27448924]
BEL-7404 tumor cell line	IC₅₀	0.01 μM Compound: GSK2126458	Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 72 hrs by MTT assay	[PMID: 26819001]
BT-474	IC₅₀	2.4 nM Compound: 1; GSk2126458	Antiproliferative activity against human BT-474 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human BT-474 cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo assay	[PMID: 24900173]
DU-145	GI₅₀	16.3 nM Compound: GSK; GSK-2126458	Growth inhibition of human DU-145 cells harboring wild type p110alpha and PTEN measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay Growth inhibition of human DU-145 cells harboring wild type p110alpha and PTEN measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay	[PMID: 33360802]
HCT-116	IC₅₀	0.01 μM Compound: GSK2126458	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 26819001]
HCT-116	IC₅₀	0.14 μM Compound: Omipalisib	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31097403]
HCT-116	IC₅₀	154 nM Compound: GSK-2126458	Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27448924]
HT-29	GI₅₀	19.9 nM Compound: GSK; GSK-2126458	Growth inhibition of human HT-29 cells harboring mutated p110alpha measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay Growth inhibition of human HT-29 cells harboring mutated p110alpha measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay	[PMID: 33360802]
MCF7	IC₅₀	0.03 μM Compound: Omipalisib	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31097403]
MDA-MB-231	IC₅₀	0.13 μM Compound: GSK2126458	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 26819001]
NCI-H1975	GI₅₀	14.4 nM Compound: GSK; GSK-2126458	Growth inhibition of human NCI-H1975 cells harboring mutated p110alpha measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay Growth inhibition of human NCI-H1975 cells harboring mutated p110alpha measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay	[PMID: 33360802]
PC-3	GI₅₀	0.25 μM Compound: 3; GSK2126458	Growth inhibition of human PC3 cells after 72 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 72 hrs by sulforhodamine B assay	[PMID: 33561608]
PC-3	GI₅₀	197 nM Compound: GSK; GSK-2126458	Growth inhibition of human PC-3 cells harboring PTEN inactivation measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay Growth inhibition of human PC-3 cells harboring PTEN inactivation measured after 72 hrs by Cell titre Glo-luminiscence cell viability assay	[PMID: 33360802]
T47D	IC₅₀	3 nM Compound: 1; GSk2126458	Antiproliferative activity against human T47D cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo assay Antiproliferative activity against human T47D cells assessed as inhibition of cell growth measured after 72 hrs by CellTiter-Glo assay	[PMID: 24900173]
U-87MG ATCC	GI₅₀	0.22 μM Compound: 3; GSK2126458	Growth inhibition of human U87MG cells after 72 hrs by sulforhodamine B assay Growth inhibition of human U87MG cells after 72 hrs by sulforhodamine B assay	[PMID: 33561608]
U-87MG ATCC	IC₅₀	537 nM Compound: GSK-2126458	Cytotoxicity against human U87MG cells after 72 hrs by MTT assay Cytotoxicity against human U87MG cells after 72 hrs by MTT assay	[PMID: 27448924]

In Vitro

Omipalisib (GSK2126458) potently inhibits the activity of common activating mutants of p110α (E542K, E545K, and H1047R) found in human cancer with K_i of 8 pM, 8 pM and 9 pM, respectively. Omipalisib causes a significant reduction in the levels of pAkt-S473 with remarkable potency in T47D and BT474 cells with IC₅₀ of 0.41 nM and 0.18 nM, respectively. Furthermore, Omipalisib (GSK2126458) leads to a G1 cell cycle arrest and produces the inhibitory effect on cell proliferation in a large panel of cell lines, including T47D and BT474 breast cancer lines with IC₅₀ of 3 nM and 2.4 nM, respectively^[1]. The combination of Omipalisib or GSK1120212 with Omipalisib enhances cell growth inhibition and decreases S6 ribosomal protein phosphorylation in drug-resistant clones from the A375 BRAF(V600E) and the YUSIT1 BRAF(V600K) melanoma cell lines^[2]. Omipalisib (GSK2126458) potentiates the antiproliferative activity of DDR1-IN-1 in colorectal cancer cell lines^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In a BT474 human tumor xenograft model, Omipalisib (GSK2126458) treatment results in a dose-dependent reduction in pAkt-S473 levels, and exhibits dose-dependent tumor growth inhibition at a low dose of 300 μg/kg. Besides, Omipalisib (GSK2126458) shows low blood clearance and good oral bioavailability in four preclinical species (mouse, rat, dog, and monkey)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 1086062-66-9
Appearance Solid
Molecular Weight 505.50
Formula C₂₅H₁₇F₂N₅O₃S
Color White to yellow
SMILES

COC1=NC=C(C=C1NS(C2=CC=C(C=C2F)F)(=O)=O)C3=CC=C(C4=C3)N=CC=C4C5=CN=NC=C5
Synonyms

GSK2126458; GSK458
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (20)

All Cell Imaging/StainingBio/Physico-chemical AssayWB

Sort by:

Journal Impact Factor

Mol Cancer

The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer. [Abstract]

2023 May 20;22(1):86. PMID: 37210549

Omipalisib purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 May 20;22(1):86. [Abstract]

Western blot of PITPNC1 expression in A549, H2009 and HPAFII cells treated for 24 h with pharmacologic inhibitors: Trametinib (MEKi, 0.5 μmol/L), BIX02189 (MEK5i, 10 μmol/L), SP600125 (JNKi, 10 μmol/L) or GSK2126458 (Omipalisib, PI3Ki, 0.1 μmol/L). Twenty μg of protein were loaded per sample. β-TUBULIN was used as loading marker.
J Hepatol

FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. [Abstract]

2021 Aug;75(2):363-376. PMID: 33887357
Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
Exp Hematol Oncol

Effects of molecularly targeted therapies on murine thymus: highly selective mTOR inhibitors induce reversible thymic involution. [Abstract]

2016 Jul 29:5:22. PMID: 27478685
Clin Cancer Res

Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. [Abstract]

2014 Nov 1;20(21):5483-95. PMID: 25186968
Cell Syst

Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. [Abstract]

2020 Jan 22;10(1):66-81.e11. PMID: 31812693

Omipalisib purchased from MedChemExpress. Usage Cited in: Cell Syst. 2020 Jan 22;10(1):66-81.e11. [Abstract]

Quantification of total nuclear EdU content in gated S-phase cells (red cells, top row, panel D; SNR cells excluded). Al:alpelisib, A8:AZD8055, D:DMSO, M:MK-2206, O:Omipalisib, R:Rapamycin, T2:Torin2. P<0.001 for each drug vs DMSO (Mann-Whitney U test).

Omipalisib purchased from MedChemExpress. Usage Cited in: Cell Syst. 2020 Jan 22;10(1):66-81.e11. [Abstract]

Time-lapse imaging of asynchronous HCC1806 cells expressing H2B:mTurquoise and mVenus:hGeminin(1-110). mTurquoise was used to score cell division and death; mVenus intensity levels were used to identify cell cycle stage, as illustrated for a representative DMSO-exposed cell. Heatmaps show the progression of 340 cells through the cell cycle after exposure to DMSO or a 0.3xGR_max dose (1 μM) of Omipalisib or Torin2 for 48h. Colors denote cell cycle stages and cell fates (see legend).

Omipalisib purchased from MedChemExpress. Usage Cited in: Cell Syst. 2020 Jan 22;10(1):66-81.e11. [Abstract]

Phenotypic responses caused by drug exposure. Shown are representative traces of mVenus fluorescence intensity vs time for single cells treated with Omipalisib (blue) or Torin2 (red). The trace for a DMSO-exposed cell is shown in the background (grey) for comparison.

Omipalisib purchased from MedChemExpress. Usage Cited in: Cell Syst. 2020 Jan 22;10(1):66-81.e11. [Abstract]

Quantification of nuclear intensity values in gated S-phase cells. Boxplots show median and 25th/75th percentiles. D:DMSO, A8:AZD8055, O:Omipalisib, T2:Torin2, AZ:AZ20, R:Rabusertib.
Ecotoxicol Environ Saf

The ROS/AKT/S6K axis induces corneal epithelial dysfunctions under LED blue light exposure. [Abstract]

2024 Nov 12:287:117345. PMID: 39541698
J Invest Dermatol

Identification of Small-Molecule Inhibitors Targeting Different Signaling Pathways in Cancer-Associated Fibroblast Reprogramming Under Tumor-Stroma Interaction. [Abstract]

2024 Jun 5:S0022-202X(24)00392-0. PMID: 38848988
Mol Cancer Ther

Navitoclax, a Bcl-2/xL Inhibitor, and YM155, a Survivin Inhibitor, in Combination with Carboplatin, Effectively Inhibit Ovarian Cancer Tumor Growth. [Abstract]

2025 Apr 28:OF1-OF13. PMID: 40293279
Front Pharmacol

CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. [Abstract]

2020 Nov 11;11:580407. PMID: 33343350
Mol Cancer Res

Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis. [Abstract]

2019 Jun;17(6):1378-1390. PMID: 30858172
Molecules

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei. [Abstract]

2020 Apr 23;25(8):1980. PMID: 32340370
Cancer Res Commun

Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer. [Abstract]

2023 Jul 12;3(7):1224-1236. PMID: 37448553
PLoS One

Omipalisib reduces hyperphosphorylated tau protein by modulating mTOR-autophagy pathway. [Abstract]

2026 Jun 23;21(6):e0352120. PMID: 42335126
Anal Methods

Estimation of the metabolic stability of omipalisib in human liver microsomes employing an ultra-fast UPLC-MS/MS approach: in silico screening for structural alarms and metabolic lability. [Abstract]

2026 Feb 5;18(5):1101-1115. PMID: 41586454
Blood Neoplasia

From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models. [Abstract]

2026 Apr 9;3(3):100230. PMID: 42294111
bioRxiv

A pharmacological toolkit for human microglia identifies Topoisomerase I inhibitors as immunomodulators for Alzheimer's disease. [Abstract]

2024 Feb 6:2024.02.06.579103. PMID: 38370689
Am J Dig Dis (Madison)

2015;2(2):95-99.
J Clin Toxicol 2014, 4:5
J Clin Toxicol

2014 October 4, 4:5.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (98.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9782 mL

9.8912 mL

19.7824 mL

5 mM

0.3956 mL

1.9782 mL

3.9565 mL

10 mM

0.1978 mL

0.9891 mL

1.9782 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[1]

BT474, HCC1954 and T-47D (human breast) are cultured in RPMI-1640 containing 10% fetal bovine serum at 37°C in 5% CO₂ incubator. Cells are split into T75 flask two to three days prior to assay set up at density which yields approximately 70-80% confluence at time of harvest for assay. Cells are harvested using 0.25% trypsin-EDTA. Cell counts are performed on cell suspension using Trypan Blue exclusion staining. Cells are then plated in 384 well black flat bottom polystyrene in 48 μL of culture media per well at 1,000 cells/well. All plates are placed at 5% CO₂, 37°C overnight and Omipalisib (GSK2126458) is added the following day. One plate is treated with CellTiter-Glo for a day 0 (t=0) measurement and read as described below. Omipalisib (GSK2126458) is prepared in clear bottom polypropylene 384 well plates with consecutive two fold dilutions. 4 μL of these dilutions are added to 105 μL culture media, after mixing the solution, 2 μL of these dilutions are added into each well of the cell plates. The final concentration of DMSO in all wells is 0.15%. Cells are incubated at 37°C, 5% CO₂ for 72 hours. Following 72 hours of incubation with Omipalisib each plate is developed and read. CellTiter-Glo reagent is added to assay plates using a volume equivalent to the cell culture volume in the wells. Plates are shaken for approximately two minutes and incubated at room temperature for approximately 30 minutes and chemiluminescent signal is read on the Analyst GT reader. Results are expressed as a percent of the t=0 and plotted against the Omipalisib (GSK2126458) concentration. Cell growth inhibition is determined for Omipalisib (GSK2126458) by fitting the dose response with a 4 or 6 parameter curve fit using XLfit software and determining the concentration that inhibits 50% of the cell growth (gIC₅₀) with the Y min as the t=0 and Y max as the DMSO control. Value from wells with no cells is subtracted from all samples for background correction..

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Knight SD, et al. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med. Chem. Lett. 2010, 1 (1), 39-43. [Content Brief]

[2]. Greger JG, et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther. 2012 Apr;11(4):909-20. [Content Brief]

[3]. Kim HG, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 2013 Oct 18;8(10):2145-50. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9782 mL	9.8912 mL	19.7824 mL	49.4560 mL
	5 mM	0.3956 mL	1.9782 mL	3.9565 mL	9.8912 mL
	10 mM	0.1978 mL	0.9891 mL	1.9782 mL	4.9456 mL
	15 mM	0.1319 mL	0.6594 mL	1.3188 mL	3.2971 mL
	20 mM	0.0989 mL	0.4946 mL	0.9891 mL	2.4728 mL
	25 mM	0.0791 mL	0.3956 mL	0.7913 mL	1.9782 mL
	30 mM	0.0659 mL	0.3297 mL	0.6594 mL	1.6485 mL
	40 mM	0.0495 mL	0.2473 mL	0.4946 mL	1.2364 mL
	50 mM	0.0396 mL	0.1978 mL	0.3956 mL	0.9891 mL
	60 mM	0.0330 mL	0.1649 mL	0.3297 mL	0.8243 mL
	80 mM	0.0247 mL	0.1236 mL	0.2473 mL	0.6182 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Omipalisib

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Rare Diseases Drug Library

Anti-Colorectal Cancer Compound Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Cosmetic Ingredient Compound Library

Posttranslational Modification Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Omipalisib

All PI3K Isoforms

All mTOR Isoforms

Biological Activity

Chemical Information

Publications (20)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Omipalisib Related Classifications

Cat. No.: HY-10297